Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Hypoxia 1Carcinoma, Hepatocellular 1

Interventions

Fluorodeoxyglucose F18 3Trastuzumab 2Melphalan 2Magnetic Resonance Spectroscopy 2FAPI-46 2Everolimus 2tipifarnib 1sargramostim 1regorafenib 1lanreotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1exemestane 1entinostat 1cabozantinib 1aldesleukin 1Tirapazamine 1Tamoxifen 1Surveys and Questionnaires 1Sorafenib 1Rose Bengal 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Quality of Life 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Tirapazamine × Endocrine × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡